HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Acelyrin (NASDAQ:SLRN) and maintained a $16 price target.
May 15, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Acelyrin and maintained a $16 price target.
The reiteration of a Buy rating and the maintenance of a $16 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100